T. Rowe Price Associates
GPCR icon

T. Rowe Price Associates’s Structure Therapeutics GPCR Stock Holding History

T. Rowe Price Associates’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.4M Sell
845,532
-1,155,164
-58% -$51.1M ﹤0.01% 917
2026
Q1 		$96.4M Buy
2,000,696
+329,558
+20% +$22.6M 0.01% 621
2025
Q4 		$116M Buy
1,671,138
+1,381,745
+477% +$56.4M 0.01% 599
2025
Q3 		$8.1M Sell
289,393
-63,475
-18% -$1.26M ﹤0.01% 1281
2025
Q2 		$7.32M Sell
352,868
-424,305
-55% -$9.33M ﹤0.01% 1184
2025
Q1 		$13.5M Sell
777,173
-617,133
-44% -$15.1M ﹤0.01% 1050
2024
Q4 		$37.8M Sell
1,394,306
-690,381
-33% -$24.5M ﹤0.01% 835
2024
Q3 		$91.5M Sell
2,084,687
-228,834
-10% -$8.85M 0.01% 590
2024
Q2 		$90.9M Buy
2,313,521
+752,571
+48% +$30.9M 0.01% 565
2024
Q1 		$66.9M Sell
1,560,950
-118,486
-7% -$5M 0.01% 645
2023
Q4 		$68.5M Sell
1,679,436
-834,127
-33% -$47.8M 0.01% 618
2023
Q3 		$127M Buy
2,513,563
+740,213
+42% +$23.9M 0.02% 471
2023
Q2 		$73.7M Buy
1,773,350
+986,845
+125% +$27.7M 0.01% 597
2023
Q1 		$18.7M Buy
+786,505
New +$18.5M ﹤0.01% 935

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

T. Rowe Price Associates's GPCR Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Structure Therapeutics (GPCR) stake by 58% in Q2 2026, selling an estimated $51.1M and leaving 845,532 shares worth $45.4M. The position accounts for ﹤0.01% of the portfolio, ranked #917.

T. Rowe Price Associates first reported a position in GPCR in Q1 2023 and has held it in 14 quarters since. The position peaked at $127M in Q3 2023. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • T. Rowe Price Associates held 845,532 shares of Structure Therapeutics worth $45.4M as of Q2 2026.
  • T. Rowe Price Associates sold 1,155,164 Structure Therapeutics shares in Q2 2026, an estimated $51.1M.
  • Structure Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #917 holding.
  • T. Rowe Price Associates first reported a position in Structure Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • T. Rowe Price Associates's Structure Therapeutics position peaked at $127M in Q3 2023.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.